Friday, January 26, 2018 10:15 PM ET
Insider Selling at Ligand Pharmaceuticals (LGND) Continues with Significant Sale
There was a significant insider sale of Ligand Pharmaceuticals shares today, as revealed in a filing with the SEC as — John L Higgins, Director and Officer — disposed of 22,500 shares in the company having a market value of approximately $3,712,500 There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 46,911 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 69,411 shares and have averaged 11,569 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Ligand Pharmaceuticals is higher than its 191-company peer group average. The Biotechnology & Medical Research peer group saw 168 buy/sell trades during this period for an average of 0.9 transactions per company. However, the number of shares traded per transaction by Ligand Pharmaceuticals insiders is lower than its peers. Within the peer group there were 26,244,358 shares purchased and 11,822,318 shares sold with company insiders purchasing 123,265 shares on average over this time period.
The data used in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2018 UpTick Data Technologies. All rights reserved.